Anebulo Pharmaceuticals, Inc. (ANEB) Tops Q1 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Anebulo Pharmaceuticals, Inc. (ANEB) Tops Q1 EPS by 7c

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

November 13, 2025 4:05 PM EST

AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or Anebulo), today announced financial results for the three months ended September 30, 2025, and recent updates.

First Quarter Fiscal Year 2026 and Subsequent Highlights:

On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose (SAD) study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant is under development for treatment of acute cannabis-induced toxicity in children. The study will... More